微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 71.06% | -10.05% | -1.88% | 30/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 72.42% | -8.4% | -7.84% | 29/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 78.58% | -2.33% | 0.65% | 21/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 78.07% | -0.7% | -1.18% | 27/160 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 79% | -0.14% | -0.08% | 26/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 79.06% | -2.65% | -1.73% | 24/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 80.46% | -3.91% | 2.34% | 24/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 78.62% | -6.29% | -0.63% | 23/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 79.11% | -2.94% | -2.59% | 23/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 81.22% | 1.02% | -3% | 22/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 83.73% | 7.37% | -0.2% | 16/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 83.89% | 0.56% | 2.92% | 22/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 81.51% | -0.68% | 1.39% | 20/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 80.4% | 2% | 3.1% | 22/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 77.98% | -2.45% | -6.53% | 19/160 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 83.43% | 6.45% | 1.66% | 17/160 | -143.08% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 82.07% | 2% | 2.66% | 16/160 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 79.94% | 2% | 1.99% | 17/160 | 55.5% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 78.38% | -3.14% | -3.14% | 23/160 | -1204.25% | 多瑞医药 | 95.59% | 行业排名> |
| 2018-12-31 | 80.92% | -1.77% | -1.77% | 21/160 | -205.91% | 微芯生物 | 95.81% | 行业排名> |
| 2017-12-31 | 82.38% | 2% | 2% | 14/160 | 52.58% | 微芯生物 | 96.09% | 行业排名> |